Phio Pharmaceuticals (NASDAQ:PHIO) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Phio Pharmaceuticals (NASDAQ:PHIO) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock.

PHIO has been the subject of a number of other reports. Wall Street Zen downgraded shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $14.00.

Phio Pharmaceuticals Stock Up 25.6%

NASDAQ:PHIO opened at $1.13 on Tuesday. Phio Pharmaceuticals has a twelve month low of $0.81 and a twelve month high of $4.19. The company has a market cap of $12.16 million, a P/E ratio of -0.53 and a beta of 0.94. The business has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $1.68.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. As a group, analysts anticipate that Phio Pharmaceuticals will post -8.54 earnings per share for the current fiscal year.

Institutional Trading of Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,694 shares of the company’s stock after buying an additional 16,108 shares during the quarter. Geode Capital Management LLC owned approximately 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent reporting period. 57.31% of the stock is currently owned by institutional investors and hedge funds.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.